You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ):創新藥HSK36212膠囊獲批臨牀
格隆匯 02-14 16:48

格隆匯2月14日丨海思科(002653.SZ)公佈,公司於近日收到國家藥品監督管理局下發的關於HSK36212膠囊(1mg;5mg;30mg)的《受理通知書》;申請事項為境內生產藥品註冊臨牀試驗。

HSK36212膠囊是公司自主研發的一種核因子相關因子通路小分子激動劑。臨牀擬用於治療慢性腎臟病及急性腎損傷引起的腎臟疾病。按我國新化學藥品註冊分類規定,其藥品註冊分類為化藥1類。

臨牀前研究表明,HSK36212膠囊在急性腎損傷與慢性腎病動物模型中表現出在分子水平上抑制腎損傷與纖維化相關基因的表達;在組織學上表現為減緩腎小球與腎小管的損傷,減輕炎症反應,在腎臟生化功能檢測中,能提升UPCR比值,改善血生化指標,表現出巨大的腎病治療潛力。

HSK36212膠囊的開發將為我國眾多急性腎損傷(AKI)和慢性腎病(CKD)患者提供一種新的更優治療選擇,具有重要的臨牀和社會意義。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account